Literature DB >> 12488710

Issues in hyperlipidemic pancreatitis.

Dhiraj Yadav1, C S Pitchumoni.   

Abstract

Hypertriglyceridemia (HTG) is a rare cause of pancreatitis. Pancreatitis secondary to HTG, presents typically as an episode of acute pancreatitis (AP) or recurrent AP, rarely as chronic pancreatitis. A serum triglyceride (TG) level of more than 1,000 to 2,000 mg/dL in patients with type I, IV, or V hyperlipidemia (Fredrickson's classification) is an identifiable risk factor. The typical clinical profile of hyperlipidemic pancreatitis (HLP) is a patient with a preexisting lipid abnormality along with the presence of a secondary factor (e.g., poorly controlled diabetes, alcohol use, or a medication) that can induce HTG. Less commonly, a patient with isolated hyperlipidemia (type V or I) without a precipitating factor presents with pancreatitis. Interestingly, serum pancreatic enzymes may be normal or only minimally elevated, even in the presence of severe pancreatitis diagnosed by imaging studies. The clinical course in HLP is not different from that of pancreatitis of other causes. Routine management of AP caused by hyperlipidemia should be similar to that of other causes. A thorough family history of lipid abnormalities should be obtained, and an attempt to identify secondary causes should be made. Reduction of TG levels to well below 1,000 mg/dL effectively prevents further episodes of pancreatitis. The mainstay of treatment includes dietary restriction of fat and lipid-lowering medications (mainly fibric acid derivatives). Experiences with plasmapheresis, lipid pheresis, and extracorporeal lipid elimination are limited.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12488710     DOI: 10.1097/00004836-200301000-00016

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  92 in total

1.  Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis.

Authors:  Jui-Hao Chen; Jiann-Horng Yeh; Hsin-Wen Lai; Chao-Sheng Liao
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

2.  Plasmapheresis in the treatment of hypertriglyceridemic pancreatitis with ARDS.

Authors:  Rajan S Kohli; Wissam Bleibel; Anil Shetty; Upendra Dhanjal
Journal:  Dig Dis Sci       Date:  2006-11-21       Impact factor: 3.199

Review 3.  Lessons learned from the clinical development and market authorization of Glybera.

Authors:  Laura M Bryant; Devin M Christopher; April R Giles; Christian Hinderer; Jesse L Rodriguez; Jenessa B Smith; Elizabeth A Traxler; Josh Tycko; Adam P Wojno; James M Wilson
Journal:  Hum Gene Ther Clin Dev       Date:  2013-06-29       Impact factor: 5.032

Review 4.  Management of acute pancreatitis in the first 72 hours.

Authors:  Theodore W James; Seth D Crockett
Journal:  Curr Opin Gastroenterol       Date:  2018-09       Impact factor: 3.287

5.  Acute pancreatitis due to hypertriglyceridemia--a case series of West Indians of Asian Indian ancestry.

Authors:  Surujpal Teelucksingh; Vijay Naraynsingh; Seetharaman Hariharan; Dilip Dan; Patrick Harnarayan; Steve Budhooram
Journal:  Indian J Gastroenterol       Date:  2009 May-Jun

Review 6.  Issues in hypertriglyceridemic pancreatitis: an update.

Authors:  John Scherer; Vijay P Singh; C S Pitchumoni; Dhiraj Yadav
Journal:  J Clin Gastroenterol       Date:  2014-03       Impact factor: 3.062

7.  Abdominal pain and milky plasma.

Authors:  Nishith K Singh
Journal:  BMJ Case Rep       Date:  2009-06-11

8.  [Rare cause of recurring necrotising pancreatitis].

Authors:  G Leder; A Formentini; M Hoffmann; D Henne-Bruns
Journal:  Chirurg       Date:  2008-03       Impact factor: 0.955

9.  [Eruptive xanthomas with hypertriglyceridemia].

Authors:  R Renner; I Teuwen; W Harth; R Treudler; J C Simon
Journal:  Hautarzt       Date:  2008-12       Impact factor: 0.751

10.  Lipemic serum in hyperlipidemic pancreatitis.

Authors:  Konstantinos Michalakis; Eleni Basiakou; Theodoros Xanthos; Panagiotis Ziakas
Journal:  Cases J       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.